Abstract
Circ_0061140 silencing repressed the progression and PTX resistance of ovarian cancer by downregulating CBX2 expression via sponging miR-136, which provided novel insight into studying the therapy of ovarian cancer with PTX.
Introduction
Ovarian cancer remains one of the most lethal gynecological malignancies, largely because patients are often diagnosed at advanced stages and eventually develop resistance to standard chemotherapies like Paclitaxel (PTX). Recent research has identified non-coding RNAs, particularly circular RNAs (circRNAs), as major players in this resistance. CircRNAs are stable, loop-shaped molecules that act as "sponges" for microRNAs (miRNAs), preventing them from suppressing oncogenic target genes. This study investigates whether a specific circRNA, circ_0061140, is the culprit behind PTX resistance in ovarian cancer through the miR-136/CBX2 axis.
Methods
The researchers employed a multi-disciplinary approach to map this molecular pathway. They developed PTX-resistant versions of standard ovarian cancer cell lines (SKOV3 and HeyA8) through chronic drug exposure. Molecular silencing was achieved using small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) to "knock down" circ_0061140 expression. The physical interaction between circ_0061140, miR-136, and the target gene CBX2 was confirmed using dual-luciferase reporter assays. Clinical relevance was assessed using 39 human ovarian cancer tissue samples (20 PTX-resistant and 19 PTX-sensitive). Finally, in vivo validation was performed using nude mouse xenograft models to observe the impact of circ_0061140 knockdown on tumor growth and drug sensitivity.
Key Results
The study found that circ_0061140 and CBX2 were significantly overexpressed in PTX-resistant tissues and cell lines, while miR-136 levels were markedly downregulated. Statistical analysis revealed a strong negative correlation ($r = -0.55$) between circ_0061140 and miR-136 in clinical samples.
Knocking down circ_0061140 significantly reduced the IC50 (the concentration of drug required to kill 50% of cells) for Paclitaxel in resistant cell lines, effectively restoring drug sensitivity. Furthermore, in vivo experiments demonstrated that the combination of circ_0061140 silencing and PTX treatment led to the most significant reduction in tumor volume and weight, proving the synergy between molecular targeting and traditional chemotherapy.
Discussion and Conclusion
The findings define a regulatory cascade: circ_0061140 → miR-136 → CBX2. In resistant states, high levels of circ_0061140 sequester miR-136, allowing the oncogene CBX2 to promote cell survival and chemoresistance. By removing this "sponge," miR-136 is freed to suppress CBX2, reversing the resistant phenotype. This suggests that PTX resistance is a reversible regulatory state rather than a permanent genetic change.
While promising, challenges remain, including the potential for miR-136 to target other genes (such as CBX4) and the limitations of immunodeficient mouse models. Future work will focus on mapping the broader miRNA network and developing effective clinical delivery systems for RNA-silencing tools in the field of nanomedicine.
Summary updated